NCT00109005View on ClinicalTrials.gov

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Melanoma
Interventions
DRUG

Revlimid

oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00109005 - Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma | Biotech Hunter | Biotech Hunter